rare disease drugs

The Export-Import Bank of Korea (Eximbank) announced on Tuesday that it will provide $150 million in project financing (PF) for developing a rare ea...

SAN DIEGO, California -- South Korea’s SK Biopharmaceuticals Co. is considering acquiring firms in the US, or the sales rights to some of thei...

South Korean pharmaceutical company Handok Inc. announced on Friday that it signed an exclusive domestic sales and distribution agreement with India...

WASHINGTON, D.C. – South Korean biosimilar giant Celltrion Inc. is accelerating its push to transform into a novel drug developer, going after...

Hyundai Motor Co. and Kia Corp. have partnered with South Korea's universities to secure materials for vehicle electrification components.Hyundai Mo...

TOKYO – SoftBank Corp., which runs LY Corp., the operator of the popular mobile messenger app Line in Japan, said on Thursday it is in talks w...

The global weight management market has entered a new chapter following the arrival of blockbuster weight-loss medication Wegovy, and South Korean l...

South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and antican...

South Korean bio-health company HK inno.N announced on Tuesday that it signed a contract with Saudi Arabian local pharmaceutical company Tabuk Pharm...

South Korea's Samsung Bioepis has received approval from the European Commission to sell Pyzchiva, a biosimilar of the autoimmune disease Stelara.&n...

Private equity giant Blackstone Inc. is set to mark its first exit from South Korea by selling a 71.25% stake in the holding firm of Geo-Young Corp....

South Korea's Celltrion Inc. announced on Thursday that it released its autoimmune disease treatment Remsima SC (infliximab) in Denmark. Remsima SC ...

Samsung Bioepis Co., a biosimilar development unit of South Korea’s top conglomerate Samsung Group, has begun its new drug development busines...

Boryung Corp., formerly Boryung Pharmaceutical Co., aims to join the 1 trillion won ($748 million) sales club this year, driven by new chronic disea...

Humans will be able to control biological age and reverse their age in 10 years with advancements in medical science and live up to around 120, abou...

South Korean biopharmaceutical giant Celltrion Inc. said on March 17 that it has launched its new autoimmune disease treatment Zymfentra in the US m...

South Korea's Celltrion Inc. announced on Wednesday that it shipped the first supply of its subcutaneous injection type of the autoimmune disease tr...

Kakao Brain, an artificial intelligence (AI) R&D subsidiary of South Korea's Kakao Corp., announced on Tuesday that it has uploaded the Labeler ...

South Korea's Daewoong Pharmaceutical announced on Monday that it has established a drug development system Daewoong AI System (DAISY) which combine...

South Korea's SK Biopharmaceuticals targeted 416 billion won ($311 million) for its epilepsy treatment Cenobamate in the US market this year. SK Bi...

South Korea's Celltrion Inc. announced on Wednesday that it will supply its autoimmune disease treatments Remsima SC (infliximab) and Yuflyma, the...

South Korea’s Kakao Healthcare Corp. has introduced an artificial intelligence-based blood sugar management solution targeting the global digi...

South Korea’s Celltrion Inc. has signed a business agreement with China’s WuXi XDC to jointly develop new antibody-drug conjugates (ADC)...

South Korea’s Celltrion Inc. announced on Thursday that it has secured supply contracts for three anticancer biosimilars in European countries...

South Korea’s LG Chem Ltd. announced on Wednesday that its US-based subsidiary Aveo Pharmaceuticals will start Phase 3 clinical trials for its...

South Korea’s snack and confectionery maker Orion Group has agreed to buy a controlling stake in LegoChem Biosciences Inc., a Korean biotech s...

Merging into one team, OCI Group and Hanmi Pharmaceutical Group will leap forward to be a global novel drug manufacturing and biotechnology innova...

South Korea's JW Pharmaceutical Corp., announced on Monday that it has received approval from the Malaysian National Pharmaceutical Regulatory Age...

South Korea’s Celltrion Inc. announced on Friday that it will supply its biosimilar Yuflyma (active ingredient: adalimumab) for the treatment ...

South Korea's Celltrion Inc. announced on Wednesday that it has applied to the US Food and Drug Administration (FDA) for a modified approval to repl...